Dr Viive Howell

Laboratory Research Director
Medicine, Northern Clinical School
Kolling Institute of Medical Research

E25 - Royal North Shore Hospital
The University of Sydney
NSW 2006 Australia

T: +61 2 9926 4758
F: +61 2 9926 4035
W: Related website

Research interests

Dr Howell’s area of interest is the genetics and molecular mechanisms of disease. Her primary focus is ovarian epithelial cancer with goals of improving understanding of the causes and progression of this disease and identification of new biomarkers which may facilitate earlier diagnosis. She is developing novel genetic mouse models of ovarian cancer in which to study the complex interplay of hormonal, genetic and other factors that leads to this disease. In addition, she is undertaking in vitro studies to search for novel regulators of signalling pathways that are implicated in ovarian cancer development.


Gynaecological cancer; Genetics; Molecular biology; Endocrinology; Cell biology


2015 | 2014 | 2013 | 2012 | 2010 | 2009


  • Kan, C., Howell, V., Hahn, M., Marsh, D. (2015), Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes, Chromosomes & Cancer. 54(1), 1-19. [Abstract]


  • Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014), Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research. 2(5), 469-479. [Abstract]
  • Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014), From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology. 27, 118-127. [Abstract]
  • Howell, V. (2014), Mice and men working together for over 100 years in the fight against cancer. Seminars in Cell & Developmental Biology. 27, 52-53. [Abstract]
  • Howell, V. (2014), Genetically engineered mouse models for epithelial ovarian cancer: Are we there yet?. Seminars in Cell & Developmental Biology. 27, 106-117. [Abstract]
  • Holt, D., Henthorn, P., Howell, V., Robinson, B., Benn, D. (2014), Succinate Dehydrogenase Subunit D and Succinate Dehydrogenase Subunit B Mutation Analysis in Canine Phaeochromocytoma and Paraganglioma. Journal of Comparative Pathology. 151, 25-34. [Abstract]
  • Howell, V., Colvin, E. (2014), Genetically Engineered Insertional Mutagenesis in Mice to Model Cancer: Sleeping Beauty. In: Methods in Molecular Biology: Vol 1194, Mouse Genetics. (pp.367-400).United States: Springer Science+Business.
  • Fuller, E., Howell, V. (2014), Culture Models to Define Key Mediators of Cancer Matrix Remodeling. Frontiers in Oncology. 4, 57. [Abstract]
  • Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakis, N., Howell, V. (2014), Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports. 4, 6152. [Abstract]


  • Parker, N., Correia, N., Crossley, B., Buckland, M., Howell, V., Wheeler, H. (2013), Correlation of MicroRNA 132 Up-regulation with an Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. Translational Oncology. 6(6), 742-748. [Abstract]
  • Tang, J., Carmichael, C., Shi, W., Metcalf, D., Ng, A., Hyland, C., Jenkins, N., Copeland, N., Howell, V., Zhao, Z., Smyth, G., Kile, B., Alexander, W. (2013), Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 110(15), 6091-6096. [Abstract]


  • Loan Le, T., Mardini, M., Howell, V., Funder, J., Ashton, A., Mihailidou, A. (2012), Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction. Hypertension. 59(6), 1164-1169. [Abstract]
  • Howell, V. (2012), Sleeping Beauty - a mouse model for all cancers?. Cancer letters. 317(1), 1-8. [Abstract]
  • Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2012), Resistance to EGFR targeted antibodies- expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). Translational Gastrointestinal Cancer. 12, 627.
  • Kan, C., Hahn, M., Gard, G., Maidens, J., Huh, J., Marsh, D., Howell, V. (2012), Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer. 12, 627. [Abstract]


  • Hahn, M., Howell, V., Gill, A., Clarkson, A., Weaire-Buchanan, G., Robinson, B., Delbridge, L., Gimm, O., Schmitt, W., Teh, B., Marsh, D. (2010), CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-related cancer. 17(1), 273-82. [Abstract]
  • Marsh, D., Howell, V. (2010), The Use of Denaturing High Performance Liquid Chromatography (DHPLC) for Mutation Scanning of Hereditary Cancer Genes. In: Methods in Molecular Biology: Cancer Susceptibility, Methods and Protocols. (pp.133-145).United States: Humana Press.


  • Howell, V., Gill, A., Clarkson, A., Nelson, A., Dunne, R., Delbridge, L., Robinson, B., Teh, B., Gimm, O., Marsh, D. (2009), Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. The Journal of clinical endocrinology and metabolism. 94(2), 434-41. [Abstract]